Clinical effect of multiple target therapy on severe IgA nephropathy with hyperuricemia of chronic progressive moderate
10.3760/cma.j.issn.1008-6315.2014.12.005
- VernacularTitle:多靶点疗法对合并高尿酸血症慢性进展性中重型IgA肾病的效果观察
- Author:
Haitao WANG
;
Ao ZHANG
;
Tianxiang LEI
;
Jurong FU
;
Guiming LI
- Publication Type:Journal Article
- Keywords:
Hyperuricemia;
IgA nephropathy;
Multi target therapy
- From:
Clinical Medicine of China
2014;30(12):1246-1249
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy of multiple target therapy in treatment of patients with chronic moderate and severe IgA nephropathy with hyperuricemia.Methods Seventy-six patients with chronic progressive moderate and severe IgA nephropathy with hyperuricemia were enrolled the current study and randomly divided into observation group and control group.Patients in control group were treated with allopurinol,prednisone,benner pury and valsartan,while those in observation group were treated with urokinase,mycophenolate mofetil besides the basis of control group for 6 months.The blood uric acid (UA),24 h urine protein,mean arterial pressure (MAP) and creatinine clearance rate (Ccr) were determined and analyzed.Results The levels of UA,24 h urinary protein,MAP and Ccr in observation group and control group were same before treatment (P ＞ 0.05).After 6 months treatment,the levels of UA,24 h urine protein,MAP and Ccr in observation group were (413.7 ± 90.7) μmol/L,(1.15 ± 0.57) g/L,(87.7 ± 10.6) mmHg and (81.9 ± 3.7) ml/min respectively,significantly different from those of the control group ((369.6 ± 67.2) μ mol/L,(0.77 ±0.51) g/L,(81.6 ±12.3) mmHg and (86.4 ±6.8) ml/min;t =2.219,2.802,2.132,3.230;P ＜0.05).The rate of adverse reactions in two groups was not significantly differnent(9.7％ (3/31) vs 9.1％ (3/33) ; x2 =0.006,P =0.936).Conclusion Multiply target therapy is effective and safe in terms of treating chronic progressive moderate and severe IgA nephropathy with hyperuricemia.
